This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.
Adverse event reporting information can be found at the bottom of the page.
Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.1
| Recipient Age | Primary Immunisation Schedule |
|---|---|
| Infants from 6 weeks to less than 6 months of age | Two doses: 1st dose (0.5ml) given from 6 weeks of age 2nd dose (0.5ml) given 2 months after 1st dose |
| Infants from 6 months of age, children, adolescents and adults | Single (0.5ml) dose |
After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination.
In previously vaccinated individuals 12 months of age and older, Nimenrix may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.
*See prescribing information for further information
†Nimenrix should be used in accordance with official recommendations
Nimenrix is available as a single pack with two needles for reconstitution and administration (23G blue and 25G orange, 25mm).2
Nimenrix is supplied as powder in a vial and solvent in a pre-filled syringe. The vaccine is reconstituted with the solvent presented in the pre-filled syringe. These components require reconstitution prior to administration.1
In one hand, hold the syringe barrel (avoid holding the syringe plunger) and unscrew the syringe cap by twisting it anti-clockwise.
Attach the needle to the syringe by twisting it clockwise into the syringe until it locks, then remove the needle protector.
Inject the solvent from the syringe into the vial containing powder to reconstitute the vaccine components.
After all the solvent has been injected into the vial, shake well to ensure all the powder has dissolved.
Once reconstituted, inspect the solution. Nimenrix should appear as a clear, colourless solution. If any foreign particulate matter is visible or there is a variation in the physical appearance, the vaccine should be discarded.
Using a new needle, administer 0.5 ml of reconstituted Nimenrix as a single intramuscular injection.
Dispose of any unused product or waste material in accordance with local requirements.
Visuals sourced and adapted from www.vecteezy.com.
Before reconstitution – Nimenrix should be stored in the refrigerator between 2°C and 8°C in its original packaging. It has a shelf life of 4 years, but the expiry date on the packaging should always be checked prior to use.
After reconstitution – Nimenrix should be used promptly following reconstitution. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If the vaccine is not used within 8 hours, it should not be administered.
References
Five educational training modules explaining meningococcal disease and who might be at increased risk, types of meningococcal vaccination and the details of Nimenrix vaccine and administration. Each is accompanied by a knowledge check Q&A resource.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
Help your customers to feel confident about vaccination - access MedISA to order printed clinic support materials to your surgery, pharmacy or other healthcare centre.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024